Valion Bio
VBIO
1 hedge funds and large institutions have $54 invested in Valion Bio in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 7 closing their positions.
2.83% less ownership
Funds ownership: 2.83% → 0% (-2.8%)
88% less funds holding
Funds holding: 8 → 1 (-7)
100% less capital invested
Capital invested by funds: $90.7K → $54 (-$90.6K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 7
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$19K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$19K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$16.3K |
| 4 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$13.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.4K |
VBIO Hedge Fund Activity: Q1 2025 in Review
1 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2025, worth a combined $54 — down 100% from $90.7K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VBIO and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was HRT Financial, exiting entirely with an estimated $19K sold.
- 1 institutional investor held Valion Bio (VBIO) as of Q1 2025, down from 8 in Q4 2024.
- Funds reported $54 of Valion Bio stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Valion Bio positions in Q1 2025 and 7 closed out, a net change of -7 holders.
- The largest Valion Bio seller in Q1 2025 was HRT Financial, an estimated $19K sold.
Based on aggregated 13F filings for Q1 2025.